GRITSTONE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7645 USD | -5.95% |
|
+2.80% | -62.52% |
| Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
| Apr. 02 | Top Midday Decliners | MT |
Presentation Operator MessageOperator (Operator)Welcome to Gritstone bio Second Quarter 2022 C...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Sector
Pharmaceuticals
Calendar
2024-04-30
- Neoantigen International Summit
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.7645
USD
Average target price
5.167
USD
Spread / Average Target
+575.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -62.52% | 86.49M | |
| -4.52% | 87.31B | |
| +2.63% | 40.86B | |
| -21.76% | 29.36B | |
| +58.56% | 24.49B | |
| -14.78% | 17.31B | |
| -18.49% | 11.62B | |
| -15.61% | 11.31B | |
| -44.02% | 11.26B | |
| +5.17% | 8.31B |
- Stock Market
- Equities
- GRTS Stock
- News Gritstone bio, Inc.
- Transcript : Gritstone bio, Inc., Q2 2022 Earnings Call, Aug 04, 2022
